Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Lehmann

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Urologia Internationalis|July 8, 2010
Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomyNorbert Marschner, Dominik Rüttinger, Gerhard Zugmaier, et al.
Molecular Medicine (Cambridge, Mass.)|May 23, 2015
Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patientsHelge Taubert, Sven Wach, Rudolf Jung, et al.
BMC Cancer|March 22, 2014
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective studyAnja Rogler, Sabine Hoja, Johannes Giedl, et al.
The Lancet. Oncology|January 25, 2011
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessmentSteven Christopher Smith, Alexander Spyridon Baras, Garrett Dancik, et al.
International Journal of Cancer|September 30, 2010
The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinomaBastian Keck, Robert Stoehr, Sven Wach, et al.
Journal of Cancer Research and Clinical Oncology|January 4, 2019
A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancerBeatrice Stubendorff, Kerstin Wilhelm, Kathleen Posselt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study GroupPeter Albers, Roswitha Siener, Susanne Krege, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2021
Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohortAndreas Hiester, Anna Fingerhut, Günter Niegisch, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)Margitta Retz, Jens Bedke, Martin Bögemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95)Jan Lehmann, Margitta Retz, Christina Wiemers, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Urologia Internationalis|July 8, 2010
Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomyNorbert Marschner, Dominik Rüttinger, Gerhard Zugmaier, et al.
Molecular Medicine (Cambridge, Mass.)|May 23, 2015
Piwil 2 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patientsHelge Taubert, Sven Wach, Rudolf Jung, et al.
BMC Cancer|March 22, 2014
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective studyAnja Rogler, Sabine Hoja, Johannes Giedl, et al.
The Lancet. Oncology|January 25, 2011
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessmentSteven Christopher Smith, Alexander Spyridon Baras, Garrett Dancik, et al.
International Journal of Cancer|September 30, 2010
The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinomaBastian Keck, Robert Stoehr, Sven Wach, et al.
Journal of Cancer Research and Clinical Oncology|January 4, 2019
A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancerBeatrice Stubendorff, Kerstin Wilhelm, Kathleen Posselt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study GroupPeter Albers, Roswitha Siener, Susanne Krege, et al.
European Journal of Cancer (Oxford, England : 1990)|August 9, 2021
Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a phase III trial cohortAndreas Hiester, Anna Fingerhut, Günter Niegisch, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)Margitta Retz, Jens Bedke, Martin Bögemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2005
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95)Jan Lehmann, Margitta Retz, Christina Wiemers, et al.
Pageof 6